Different mechanisms of GIP and GLP-1 action explain their different therapeutic efficacy in type 2 diabetes
Eleonora Grespan, Toni Giorgino, Andrea Natali, Ele Ferrannini, Andrea Mari
Topics & Concepts
IncretinType 2 diabetesInternal medicineEndocrinologyLong-term potentiationGastric inhibitory polypeptideMedicineHormoneGlucagon-like peptide-1In vivoInsulinDiabetes mellitusReceptorBiologyGlucagonBiotechnologyDiabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and LipoproteinsPancreatic function and diabetes